ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 91 filers reported holding ONCOMED PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.28 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,012,000 | -69.8% | 490,707 | -66.7% | 0.48% | -71.9% |
| Q3 2017 | $6,658,000 | +8.7% | 1,473,061 | -19.9% | 1.70% | +18.4% |
| Q2 2017 | $6,126,000 | -63.8% | 1,839,730 | 0.0% | 1.44% | -65.5% |
| Q1 2017 | $16,944,000 | +19.5% | 1,839,730 | 0.0% | 4.17% | +6.7% |
| Q4 2016 | $14,184,000 | -27.7% | 1,839,730 | 0.0% | 3.90% | +5.7% |
| Q3 2016 | $19,617,000 | -13.4% | 1,839,730 | 0.0% | 3.70% | -0.3% |
| Q2 2016 | $22,647,000 | +21.8% | 1,839,730 | 0.0% | 3.71% | +9.2% |
| Q1 2016 | $18,600,000 | -55.1% | 1,839,730 | 0.0% | 3.40% | -54.5% |
| Q4 2015 | $41,468,000 | +50.2% | 1,839,730 | +10.6% | 7.46% | +27.2% |
| Q3 2015 | $27,600,000 | -26.3% | 1,663,650 | 0.0% | 5.86% | +4.2% |
| Q2 2015 | $37,432,000 | -12.7% | 1,663,650 | 0.0% | 5.63% | -17.7% |
| Q1 2015 | $42,888,000 | – | 1,663,650 | – | 6.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |